Citation: Erin N. Bodine, Connor Cook, Mikayla Shorten. The potential impact of a prophylactic vaccine for Ebola in Sierra Leone[J]. Mathematical Biosciences and Engineering, 2018, 15(2): 337-359. doi: 10.3934/mbe.2018015
[1] | James P. Gander . Market Value Volatility and the Volume of Traded Stock for U.S. Industrial Corporations. Quantitative Finance and Economics, 2017, 1(4): 403-410. doi: 10.3934/QFE.2017.4.403 |
[2] | Elyas Elyasiani, Luca Gambarelli, Silvia Muzzioli . The Information Content of Corridor Volatility Measures During Calm and Turmoil Periods. Quantitative Finance and Economics, 2017, 1(4): 454-473. doi: 10.3934/QFE.2017.4.454 |
[3] | Mehmet F. Dicle . US Implied Volatility as A predictor of International Returns. Quantitative Finance and Economics, 2017, 1(4): 388-402. doi: 10.3934/QFE.2017.4.388 |
[4] | Osarumwense Osabuohien-Irabor, Igor M. Drapkin . FDI Escapism: the effect of home country risks on outbound investment in the global economy. Quantitative Finance and Economics, 2022, 6(1): 113-137. doi: 10.3934/QFE.2022005 |
[5] | Keming Li . Relative mispricing and takeover likelihood. Quantitative Finance and Economics, 2021, 5(4): 689-715. doi: 10.3934/QFE.2021031 |
[6] | Charlotte Christiansen, Christos S. Savva . Government bond market risk-return trade-off. Quantitative Finance and Economics, 2023, 7(2): 249-260. doi: 10.3934/QFE.2023013 |
[7] | Tolga Tuzcuoğlu . The impact of financial fragility on firm performance: an analysis of BIST companies. Quantitative Finance and Economics, 2020, 4(2): 310-342. doi: 10.3934/QFE.2020015 |
[8] | Lorna Katusiime . Time-Frequency connectedness between developing countries in the COVID-19 pandemic: The case of East Africa. Quantitative Finance and Economics, 2022, 6(4): 722-748. doi: 10.3934/QFE.2022032 |
[9] | Gerasimos G. Rompotis . The impact of taxation on firm performance and risk: Evidence from Greece. Quantitative Finance and Economics, 2024, 8(1): 29-51. doi: 10.3934/QFE.2024002 |
[10] | Jorge A. Chan-Lau . Systemic centrality and systemic communities in financial networks. Quantitative Finance and Economics, 2018, 2(2): 468-496. doi: 10.3934/QFE.2018.2.468 |
Abbreviations:
DSD = Disorders of Sex DevelopmentDisorders of Sex Development (DSD) are congenital conditions defined by atypical chromosomal, gonadal or anatomic sex [1]. The estimated incidence of genital ambiguity is 1 in 5000 to 1 in 4500 births [2, 3, 4]. The most recent classification is based on chromosomal setting: DSD related to sex chromosome abnormalities and DSD related to 46,XY or 46,XX karyotype [5]. 45,X/46,XY mosaicism, included in sex chromosome abnormalities DSD, have an overall incidence of about one in 10.000 [6].
45,X/46,XY mosaicism is characterized by heterogeneous clinical presentation [7, 8, 9, 10]. Most prenatally diagnosed subjects (90‒95%) present normal male phenotype at birth; abnormalities are only found in a small percentage (5‒10%) [7, 10, 11, 12]. Data derived from postnatally ascertained cases exaggerate the extent of genital and other abnormalities by over representing the phenotypically abnormal minority [7].
Possible genital presentations are: male or female regular, males with ambiguous features and hypovirilization (micropenis, lack of scrotal fusion, incomplete testicular descent, hypospadia) or females with ambiguous features and virilization (clitoromegaly, labio-scrotal fusion) [7, 8, 9, 10]. Typical somatic signs of the Turner syndrome are observed in some cases (palpebral ptosis, epicanthus, webbed neck, short stature, shield chest, scoliosis) with possible prenatal and postnatal growth retardation [10, 13]. Short stature may be the only somatic feature [10, 13, 14], which is usually related to the SHOX (“Short Stature Homeobox”) gene haploinsufficiency in 45,X cell line [15, 16]. Some development abnormalities can be associated to 45,X/46,XY mosaicism: heart malformations, kidney malformations, Meckel diverticulum, bilateral inguinal hernias [7, 8]. As regards to gonads, functional testes can more often occur and streak or dysgenetic gonads are also possible, even in the presence of normal male external genitalia [7]. Gonads can be set at any point of the testicular descent path: streak gonads are found most frequently at intra-abdominal level, while regularly developed testes often reach inguinal-scrotal level [17]. There is a higher risk of neoplastic transformation in dysgenetic gonads, which is not limited to subjects with abnormal genitalia [7]. The incidence of gonadoblastoma in 45,X/46,XY individuals is reported to be approximately 15% [11, 18]. In rare cases ovary stromal-like tissue with scattered primordial follicles has been observed [12]. Müllerian structures are occasionally found, resulting from absent or inadequate production of anti-Müllerian hormone by Sertoli cells [12].
The treatment of individuals with DSD requires the attention of many professionals. Although the medical-surgical treatment is highly important, quality of life also largely depends on the psychosocial management [19]. There is little data concerning the clinical course of people with 45,X/46,XY mosaicism and, in particular, psychosocial development has not been adequately investigated [20, 21].
This study focuses on methods that enable clinicians to investigate the alignment of physical characteristics, gender identity and quality of life in people with DSD. In particular, the study reports the application of these methods to a small cohort of people with 45,X/46,XY.
The aim of the study was to describe the physical phenotypes of a cohort of children and young adults with 45,X/46,XY mosaicism, psychosocial features focusing on gender identity in children and assessment of quality of life in young adults. A scoring system was proposed in order to make it easier to understand the process of gender identification and quality of life in DSD patients with specific physical phenotypes.
We analyzed the personal histories of ten subjects with 45,X/46,XY mosaicism followed up between 1985 and 2014 in the Department of Pediatric Endocrinology, Regina Margherita Children’s Hospital, Turin: five children and five young adults, four reared as females and six as males. These subjects represent the entire consecutive series of patients with 45,X/46,XY mosaicism followed up in the hospital in the specific time period.
Table 1 summarizes clinical presentation, sex of rearing, gonadal features, genitourinary imaging and laboratory investigations in the first month of life in the ten subjects with 45,X/46,XY mosaicism. Reconstructive and gonadal surgeries are also presented.
Subject | Clinical presentation/Sex of rearing | Reconstructive surgery (age: years, months) | Gonadal features | Gonadal surgery (age: years, months) | Karyotype | Genitourinary imaging | Hormone levels (10th‒30th day of life) | Comorbidities |
1 | EMS 4.5/12 Female | Clitoroplasty (1, 0/12) Vaginoplasty (1, 0/12) | Right gonad: streak, intra-abdominal Left gonad: dysgenetic, inguinal | Bilateral gonadectomy (0, 3/12) | 45,X/46,XY prenatal (amniocentesis) | Uterus: present, hypoplastic Fallopian tubes: absent Urogenital sinus | FSH 3.6 mU/mL LH 2.4 mU/mL Testosterone 0.56 ng/mL | Horizontal nystagmus |
2 | EMS 0.5/12 Female | Vaginoplasty (0, 6/12) Clitoroplasty (0, 6/12–25, 0/12) Corrective surgery in vaginal introitus stenosis (25, 0/12) | Right gonad: streak, intra-abdominal Left gonad: dysgenetic, inguinal | Bilateral gonadectomy (0, 4/12) | 45,X/46,XY postnatal | Uterus: present, regular structure Fallopian tubes: absent Urogenital sinus | FSH 3.5 mU/mL LH 2.1 mU/mL Testosterone 0.42 ng/mL | None |
3 | EMS 9.5/12 Female | Vaginoplasty (1, 0/12) Clitoroplasty (1, 0/12) | Right gonad: streak, inguinal Left gonad: dysgenetic, intrascrotal | Bilateral gonadectomy (1, 0/12) | 45,X/46,XY prenatal (amniocentesis) | Uterus: present, regular structure Fallopian tubes: present on right side Female urethra: slightly longer, it flows in a small vestibule with a vagina of regular morphology | FSH 3.1 mU/mL LH 2.5 mU/mL Testosterone 0.3 ng/mL | None |
4 | EMS 4.5/12 Female | Vaginoplasty (0, 3/12) Clitoroplasty (0, 3/12) | Right gonad: dysgenetic, inguinal Left gonad: streak, intra-abdominal | Bilateral gonadectomy (0, 3/12) | 45,X/46,XY prenatal (amniocentesis) | Suspected ambiguous genitalia at prenatal ultrasound Uterus: present, regular structure Fallopian tubes: absent Vagina with moderate uterine impression at cupola level Female urethra: straight, veru montanum absent, it flows in a large vestibule with a vagina of regular morphology | FSH 11.1 mU/mL LH 6.14 mU/mL Testosterone 1.12 ng/mL | None |
5 | EMS 5/12 Male | Urethroplasty (12, 0/12) Testicular prosthesis placement (18, 10/12) | Right gonad: streak, intra-abdominal Left gonad: dysgenetic, intra-abdominal | Bilateral gonadectomy (1, 6/12) | 45,X/46,XYq- postnatal | Uterus: absent Fallopian tubes: absent Male urethra: hypospadic, veru montanum present | FSH 3.5 mU/mL LH 0.7 mU/mL Testosterone 0.8 ng/mL | None |
6 | EMS 6.5/12 Male | Chordee correction (recurvatio corrective surgery) (3, 0/12) Urethroplasty (4, 5/12) | Right gonad: regularly developed, intrascrotal Left gonad: dysgenetic, inguinal | Left gonadectomy (1, 9/12) | 45,X/46,XY postnatal | Uterus: absent Fallopian tubes: absent Male urethra: hypospadic, veru montanum present | FSH 5.4 mU/mL LH 3.2 mU/mL Testosterone 1.2 ng/mL | None |
7 | EMS 8.5/12 Male | Chordee correction (recurvatio corrective surgery) (8, 0/12) Urethroplasty (8, 0/12) | Right gonad: hypoplastic, inguinal Left gonad: regularly developed, intrascrotal | Right orchidopexy (6, 0/12) | 45,X/46,XY/47,XYY postnatal | Uterus: absent Fallopian tubes: absent Male urethra: hypospadic | FSH 4.5 mU/mL LH 2.3 mU/mL Testosterone 0.9 ng/mL | None |
8 | EMS 7.5/12 Male | Chordee correction (recurvatio corrective surgery) (1, 6/12) Urethroplasty (in two times) (2, 0/12–3, 6/12) | Right gonad: fusiform, inguinal Left gonad:dysgenetic, intra-abdominal | Right orchidopexy (0, 3/12) Left gonadectomy (0, 3/12) | 45,X/46,X, i(Y)(p11) postnatal | Uterus: absent Fallopian tubes: absent Male urethra: hypospadic, veru montanum present | FSH 11.2mU/mL LH 5.1mU/mL Testosterone 1.5ng/mL | Common Atrioventri-cular Chamber |
9 | EMS 7.5/12 Male | Hysterectomy (1, 0/12) Vaginectomy (1, 0/12) Urethroplasty (in two times) (2, 4/12–3, 0/12) | Right gonad: regularly developed, inguinal Left gonad: streak, intra-abdominal | Right orchidopexy (0, 4/12) Left gonadectomy (0, 4/12) | 45,X/46,XY postnatal | Suspected ambiguous genitalia at prenatal ultrasound Uterus: present, regular morphology Fallopian tubes: present on left side, hypoplastic Urogenital sinus in which a straight urethra flows, veru montanum absent | FSH 1.2 mU/mL LH 0.8 mU/mL Testosterone 0.3 ng/mL | None |
10 | EMS 12/12 Male | None | Right gonad: regularly developed, intrascrotal Left gonad: regularly developed, intrascrotal | None | 45,X/46,XY prenatal (amniocentesis) | Uterus: absent Fallopian tubes: absent Male urethra | FSH 4.5 mU/mL LH 1.4 mU/mL Testosterone 1.3 ng/mL | None |
Clinical presentation and history were assessed using specific measures, that are described below.
For the children, we analyzed gender identification by means of the Gender Identity Questionnaire for Children (GICQ), which was filled in by the parents [22].
For the young adults we used the World Health Organization Quality of life Assessment (WHOQOL-100) [23, 24, 25] in order to assess their quality of life.
Feature | Score for Yes/No or condition |
EMS | |
Scrotal fusion | 3/0 |
Micropenis | 0/3 |
Urethral meatus | |
- Normal | 3 |
- Glandular | 2 |
- Penile | 1 |
- Perineal | 0 |
Right and left gonad (score for each) | |
- Scrotal | 1.5 |
- Inguinal | 1 |
- Abdominal | 0.5 |
- Absent | 0 |
When selecting the sex of rearing, genital anatomy, surgical options, need for lifelong hormone replacement therapy, potential for fertility were taken into consideration. Genital anatomy was the most important aspect on which the decision was based. In the past, the presence of uterus was an indication for attributing female sex, while recently parental involvement in the decision has progressively grown, since consistent parental support is felt to be critical for the patient for assimilating sex assignment.
Due to genital ambiguity at birth, karyotype was carried out on six subjects in order to determine
the chromosomal sex; it was carried out prenatally for the remaining four by means of amniocentesis
and was then confirmed at birth.
Genitourinary imaging was obtained by carrying out retrograde genitography and
abdominopelvic ultrasound, in some cases completed by means of abdomen magnetic resonance.
Retrograde genitography was performed for the anatomical outlining of the urogenital sinus and for
localizing the position and entry ofthe urethra and vagina into the sinus. Abdominopelvic ultrasound
and abdomen magnetic resonance were used for evaluating internal genitalia. Intwo subjects, signs of
genital ambiguity has already been detected with prenatal ultrasound.
The following hormones were investigated using standard methods in the first month of life (from 10th
to 30th day of life):
· Follicle Stimulating Hormone (FSH);
· Luteinizing Hormone (LH);
· Testosterone.
Complete clinical evaluation of each patient, in particular through renal ultrasound and
echocardiography, was performed at birth in order to detect pathologies of any kind.
The patients were evaluated and followed up between 1985 and 2014 in the Department of Pediatric Endocrinology, Regina Margherita Children’s Hospital, Turin, Italy. The clinical course of each subject was monitored with annual outpatient checkups carried out by the pediatric endocrinologist as case manager. The clinical history was collected at each checkup, a general physical examination was performed and the following parameters were assessed: height, weight, growth rate, pubertal development according to Tanner staging [27].
In clinical histories, the attitudes and decisions concerning the following issues were analyzed:
· diagnosis and sex of rearing;
· reconstructive interventions;
· cancer risk management and preventive decisions in relation to gonadal function;
· growth pattern and human growth hormone therapy;
· pubertal development and sex hormone replacement therapy;
· gender identity in children and quality of life in young adults.
At the end of the follow up, in order to evaluate the alignment of phenotypic features to the attributed sex, we elaborated a clinical scoring system (rating from 1 = low alignment to 5 = high alignment) relative to: height, genital appearance, presence of gonads and pubertal development (Table 3).
Feature | Score |
Height | |
< 3rd percentile 3rd‒10th percentile 10th‒25th percentile 25th‒50th percentile > 50th percentile | 1 2 3 4 5 |
Male genitals | |
hypospadias and recurvatio hypospadias and surgically corrected recurvatio surgically corrected hypospadias and recurvatio surgically corrected hypospadias and no recurvatio male normally shaped genitalia | 1 2 3 4 5 |
Female genitals | |
clitoral hypertrophy and urogenital sinus partial reduction of clitoral hypertrophy and urogenital sinus clitoroplasty and vaginoplasty with narrow orifice clitoroplasty and vaginoplasty female normally shaped genitalia | 1 2 3 4 5 |
Gonads | |
bilateral gonadectomy unilateral gonadectomy of a streak gonad and contralateral dysgenetic gonad bilateral dysgenetic gonads unilateral gonadectomy of a streak gonad and contralateral regularly developed gonad bilateral regularly developed gonads | 1 2 3 4 5 |
Pubertal development score: according to Tanner staging [27]. |
The analysis of clinical histories highlighted a clinical outcome (height reached at the end of the follow up, results of reconstructive and gonadal surgeries, pubertal development) which the pediatric endocrinologist quantified for each subject by means of the clinical scoring system. The scores are shown in Table 4 in the “Total Clinical Scores” column; in the third, fourth, fifth and sixth columns the score for each specific feature is reported in brackets.
Subject | Age (years, month) | Height (clinical score) | Genitalia (clinical score) | Gonads (clinical score) | Pubertal development (clinical score) | Total Clinical Score | Gicq score | Whoqol-100 score | Comorbidities | |
TOTAL SCORE | 4 FACETS SCORE | |||||||||
1 | 33, 0/12 | 144.1 cm << 3rd percentile (1) | Clitoroplasty and vaginoplasty results (4) | Bilateral gonadectomy results (1) | Adult (BV, PHV) with regular menses (5) | 11/20 = 55% | - | - | - | Recurrent urinary tract infections; neurological disease (tremors, motor incoordination, nystagmus, cognitive impairment); erythematous desquamative chronic dermatitis |
2 | 31, 0/12 | 153.5 cm 3rd-10th percentile (2) | Clitoroplasty, vaginoplasty and corrective surgery in vaginal introitus stenosis results (4) | Bilateral gonadectomy results (1) | Adult (BV, PHV) with regular menses (5) | 12/20 = 60% | - | 87.5% | Self-esteem: 87.5% Body image: 93.75% Interpersonal relationships: 93.75% Sexual activity: 93.75% Average: 92.2% | None |
3 | 18, 0/12 | 158.5 cm 25th percentile (3) | Clitoroplasty results, presence of vaginal introitus stenosis (3) | Bilateral gonadectomy results (1) | Adult (BV, PHV) with regular menses (5) | 12/20 = 60% | - | 68.75% | Self-esteem: 62.5% Body image: 56.25% Interpersonal relationships: 68.75% Sexual activity: 0% Average: / | Overweight (BMI: 30 kg/mq), autoimmune thyroiditis |
4 | 1, 0/12 | 72 cm > 50th percentile (5) | Clitoroplasty and vaginoplasty results (4) | Bilateral gonadectomy results (1) | Prepubertal (-) | 10/15 = 66.7% | - | - | - | None |
5 | 26, 11/12 | 166.2 cm > 10th percentile (3) | Urethroplasty results; intrascrotal testicular prosthesis (4) | Bilateral gonadectomy results (1) | Adult (PHV, GV) (5) | 13/20 = 65% | - | - | - | Slight overweight (BMI: 26 kg/mq) |
6 | 19, 0/12 | 152.8 cm << 3rd percentile (1) | Chordee correction and urethroplasty results (3) | Rright gonad: intrascrotal, 25 mL (periodic monitoring with scrotal ultrasound and markers assessment: βhCG and αFP); Left gonad: gonadectomy results (4) | Adult (PHV, GV) (5) | 13/20 = 65% | - | 43.75% | Self-esteem: 81.25% Body image: 31.25% Interpersonal relationships: 75% Sexual activity: 6.25% Average: 48.3% | Slight overweight (BMI: 27.3 kg/mq) |
7 | 8, 0/12 | 125.8 cm 25th-50th percentile (4) | Chordee correction and urethroplasty results (3) | Right gonad: intrascrotal, 1 mL (periodic monitoring with scrotal ultrasound); Left gonad: intrascrotal, 2 mL (periodic monitoring with scrotal ultrasound) (5) | Prepubertal (-) | 12/15 = 80% | 4.80/5 = 96% | - | - | None |
8 | 6, 3/12 | 104.6 cm < 3rd percentile (1) | Chordee correction and urethroplasty results (3) | Right gonad: intrascrotal, fusiform, 1 mL (periodic monitoring with scrotal ultrasound); Left gonadectomy results (2) | Prepubertal (-) | 6/15 = 40% | 4.90/5 = 98% | - | - | Mitral regurgitation of moderate degree, hemodynamically stable (result of intervention to the atrioventricular common chamber) |
9 | 5, 2/12 | 95.5 cm < 3rd percentile (1) | Vaginectomy and urethroplasty results (3) | Right gonad: intrascrotal, 2 mL (periodic monitoring with scrotal ultrasound); Left gonadectomy results (4) | Prepubertal (-) | 8/15 = 53.3% | 4.80/5 = 96% | - | - | None |
10 | 4, 10/12 | 110 cm 50th-75th percentile (5) | Normal conformed, no reconstructive surgery (5) | Intrascrotal, 2 mL (periodic monitoring with scrotal ultrasound) (5) | Prepubertal (-) | 15/15 = 100% | 4.36/5 = 87.2% | - | - | None |
In order to evaluate gender identity and quality of life, the children’s parents were given a questionnaire on gender identity while the young adults filled in a questionnaire on quality of life.
At the time of the interview, each subject was informed of the purpose of the study; then the patients and the children’s parents released their informed consent. Parental consent was required for those under 14 years of age, for subjects between 14 and 18 years of age the consent of patients and their parents was required, while subjects over 18 years of age signed their own informed consent.
The 16-item Gender Identity Questionnaire for Children was taken from a study originally carried out by P.H. Elizabeth and R. Green in 1984, in order to create a tool that assessed possible problems in gender identity development. In 2004 Johnson and colleagues presented the psychometric properties of this parent-report instrument after making a few changes. The final 14-item questionnaire has excellent psychometric properties, therefore Johnson and colleagues proposed it as a useful and affordable screening tool, characterized by quick and easy administration [22]. Each item is rated on a 5-point scale for frequency of occurrence, except for 3 items which also have a ‘not applicable’ option; the score ranges from 1 (more cross-gendered behavior) to 5 (more same-gendered behavior). A mean GIQC score was calculated (gender-referred group mean score: 2.83).
The Italian version of this questionnaire was developed in the Department of Psychology, at the University of Turin using the translation/back-translation method in order to assure equivalence in meaning. The pilot study in which the psychometric properties of the tool were explored [28] showed that this questionnaire can be used for measuring children’s gender-related behavior in the Italian context. The preliminary statistical analysis indicated that excluding two of the items significantly increased the reliability of the questionnaire (Cronbach’s Alpha 0.83). The mean score of the non-clinical Italian group was 4.31 which was similar to that of the original study carried out by Johnson and colleagues in which the control group showed a mean score of 4.20.
In line with the preliminary results of the pilot study on the Italian version of the GIQC, in our data analysis we calculated the score on the 12 items for evaluating our patients. We were able to use this tool thanks to the availability and cooperation of the research group from the Department of Psychology lead by the scientific coordinator Prof. Piera Brustia.
The World Health Organization Quality of Life assessment (WHOQOL-100) filled in by the young adults was implemented by the World Health Organization in order to develop a quality of life assessment that would be applicable cross-culturally [23, 24, 25].
The WHOQOL is divided into six broad domains of quality of life. These are:
(a) physical domain (the individual’s perception of his/her physical status);
(b) psychological domain (the individual’s perception of his/her cognitive and affective status);
(c) level of independence;
(d) social relationships (the individual's perception of interpersonal relationships and social role);
(e) environment; and
(f) spirituality/religion/personal beliefs (the individual's perception of life meaning).
Within each domain there are several quality of life sub-domains (facets) that summarize the particular domain of quality of life.
This questionnaire provides a percentage global score concerning quality of life (cut off 50%: over 50% good quality of life, under 50% poor quality of life), which incorporates 24 specific facets belonging to the six domains of Quality of Life [23, 24, 25].
In our study, 4 of the 24 facets were assessed due to their important implication in quality of life and gender identity:
1. self-esteem,
2. body image,
3. interpersonal relationships,
4. sexual activity.
The reconstructive and gonadal surgical operations performed on the ten patients and the ages at which the operations were carried out are reported in Table 1.
The four female subjects underwent early feminizing reconstructive surgery. Subject 2 underwent corrective surgery in order to repair vaginal introitus stenosis and review clitoroplasty at 25 years of age. There is generally need for further intervention of possible vaginal introitus stenosis, subsequent to early vaginoplasty in these subjects after pubertal age [1, 29, 30].
The four female subjects underwent early bilateral gonadectomy due to the presence of streak or dysgenetic gonads in order to prevent malignancy and psychological problems with the presence of testes in subjects reared as females. At histological examination gonadoblastoma was not detected in any of the cases.
In the six male subjects, reconstructive surgery had a greater variability in timing which was often performed later in life. Gonadectomy was carried out in the presence of streak or dysgenetic gonads: the decision of removing them depended on the absence of hormone production and of spermatogenesis process in the presence of significant cancer risk. At histological examination gonadoblastoma was not detected in any of the cases.
Gonadectomy was not performed on subjects with apparently regularly developed testes, because of their possible hormone production and consequent spontaneous pubertal development.
Orchidopexy to the scrotum was performed on cryptorchid subjects.
In females, subject 1 received hGH therapy for 7 years (from the age of 9 years and 3 months to the age of 16 years and 5 months) and she reached a final height below the 3rd percentile (Figure 1). The growth pattern of subject 2 was stable at the 3rd percentile up to 10 years of age, reaching final height between the 3rd and 10th percentile following a 6 year course of hGH therapy (from the age of 10 years and 1 month to the age of 16 years and 3 months) (Figure 1). Subject 3 presented an initially normal growth pattern that reached its peak at the 75th percentile at 7 years of age after which there was a reduced growth pattern: hGH therapy was carried out from the age of 14 years and 2 months to the age of 15 years and 8 months with the achievement of final height at the 25th percentile (Figure 1).
The three young adults reared as females underwent sex hormone replacement therapy and reached complete adult development (according to Tanner staging) with regular menses (Figure 1).
Subject 4, a 12-month-old female, has not yet been submitted to any type of therapy.
In males, particular care was taken when considering hGH therapy due to the possible neoplastic risk in their potentially dysgenetic gonads submitted to such a proliferative stimulus. Following early bilateral gonadectomy, hGH therapy was administered to subject 5 from the age of 9 years and 8 months to the age of 15 years and 4 months: he reached final height above the 10th percentile. From the age of 12 years and 2 months he was administered testosterone (Figure 2). Therapy with human growth hormone was not administered to subject 6 because of noncompliance partially due to his concern about the possible neoplastic risk: his final height was below the 3rd percentile. His preserved gonad produced testosterone normally and spontaneous pubertal development occurred (Figure 2). The growth and gonadal features of the remaining four subjects (7-8-9-10) will be evaluated in the future as they were still in childhood at the end of the follow-up.
Table 4 shows the results of the gender identity questionnaire (GIQC) that was filled in by the parents of the four children (subjects 7-8-9-10) reared as males. The scores were high, indicating that the children developed and maintained a gender identity commensurate with the assigned sex.
It was not possible to investigated specific items of gender identity of subject 4 (the only child reared as female) since most of gender-related behaviors typically occur from 2‒3 years of age, therefore her parents were not requested to fill in the questionnaire.
The WHOQOL-100 questionnaire was administered to the young adults in order to evaluate quality of life and the results are reported in Table 4.
The WHOQOL-100 questionnaire was not administered to subject 1 (reared as female) due to her cognitive impairment and to subject 5 (reared as male) because his family has opposed to prior attempts to interview him about his clinical condition.
We compared clinical assessment with the results obtained from the questionnaires (GIQC in children and WHOQOL-100 in adults) as score percentages.
It was not possible to evaluate the female children due to the age of the only child reared as female (subject 4).
For the male children we compared the clinical scores with the results of the questionnaire on gender identity (GIQC) (Table 4). Clinical scores in children included height, genital and gonadal features (total score = 15), as it was too early to assess pubertal development.
The male children developed gender behavior in line with the assigned sex. In subjects 7-8-9 GICQ score was higher than the clinical score; in subject 10 GICQ score was 87.2%, which was lower than the clinical score (100%).
The comparison of the young adults’ clinical scores with the results of WHOQOL-100 questionnaire is reported in Table 4. The total scores of the 6 areas and of the 24 facets were evaluated. Among them, the following facets were subjected to further analysis (4-facets score):
1. self-esteem,
2. body image,
3. interpersonal relationships,
4. sexual activity.
For the only two female subjects the comparison between the clinical scores and questionnaire results showed that in subject 2 the total quality of life score and the 4-facets score were above 80%, thus exceeding the clinical score (60%); in subject 3 the total quality of life score was above 60% and similar to the clinical score (60%), while the 4-facets score was incomplete since she declined to answer the questions concerning her sexual activity (Table 4).
For the only young adult male who completed the questionnaire, the total quality of life score and the 4-facets score were below 50%, while the clinical score was 60% (Table 4).
Sex of rearing attribution in subjects with disorders of sex development depends on various issues: diagnosis, genital anatomy, surgical options, need for lifelong replacement therapy, potential for fertility, parental opinion and cultural practices [1, 2]. The traditional approach which was mainly based on the physician’s perspective and enabled him to attribute female sex on the basis of easier surgery [1, 31] has progressively been overcome by the growing influence of parental opinion based mainly on personal and social experience. Early assignment of sex is necessarily grounded on the surrogate will of the parents [32]. Further information regarding the wellbeing of subjects with DSD from childhood to adult age is required in order to implement an appropriate strategy for assigning sex.
There is little or no available data on gender identity in DSD subjects: Meyer-Bahlberg found that, in genetic females with congenital adrenal hyperplasia, 5% expressed gender dysphoria, a much higher rate than that typically quoted and a few women transitioned from female to male gender [33]; Mazur affirmed that gender change from assigned-female to male is nil in complete androgen insensitivity syndrome [34]; Cohen-Kettenis and Reiner observed that gender change from female to male occurred in approximately 60% of XY DSD individuals who were assigned female as their sex of rearing at birth but with normal prenatal testosterone effects [35] and finally it was observed that gender change from female to male occasionally occurs in XY DSD individuals with low prenatal testosterone effects almost all of whom are assigned female at birth as their sex of rearing [36]. Only few studies regarding gender identity and psychosocial development in 45,X/46,XY mosaicism can be found in the literature [20, 21].
Considering that active prenatal androgen effects appeared to dramatically increase the likelihood of recognition of male sexual identity independent of sex of rearing, we can assume that in our cohort there may have been partially deficient prenatal brain androgenisation [37].
It is essential to consider that patients with DSD are a heterogeneous group regarding gender identity and gender role outcome when planning treatment. In recent years there has been a shift toward multidisciplinary evaluation and treatment of DSD with the active involvement of the patient and family [38].
We propose methods for facilitating the association between physical findings and gender identification and quality of life in DSD studies. This study reports the use of these methods on a small cohort of subjects with 45,X/46,XY mosaicism divided into two age groups: children and young adults.
In children the limitations of our study were incomplete growth and pubertal development. In this age group strong identification with the assigned sex was observed, which was even stronger in those who had surgically reconstructed genitalia. Previous studies underline that gender identification in DSD appears to be less problematic during the early and middle stages of childhood than during adolescence and adulthood [39].
The Gender Identity Questionnaire for Children data show that the four-year-old male child with normal genital phenotype (subject 10) had a gender identity score of 87.2%, while the other children with genital anomalies had higher identity scores. In our opinion in subject 10, stereotypic male behavior,typical of mid childhood, was not so evident considering his age, while in the others, it was amplified to confirm the belonging to male gender.Nevertheless it is important to note that during childhood the correlation between gender identity and phenotypic appearance can be incomplete. Therefore it is essential to follow up the evolution of gender identity in these children especially at pubertal age, which is a critical phase for psychosexual development [40].
For theyoung adults quality of life was investigated by means of the WHOQOL questionnaire. There is a lack of consensus concerning conceptualization, operational definition and measurement of quality of life since it is actually an umbrella term covering various aspects such as functioning, health status, perceptions, life conditions, behavior, happiness, lifestyle and symptoms [41]. The WHOQOL questionnaire investigates quality of life from a broad perspective including: physical domain, psychological domain, level of independence, social relationships, environment and spirituality/religion/personal beliefs [23, 24, 25].
In the cases of the two young female adults (subject 2 and 3) the clinical scores were not balanced with quality of life scores: in fact they had similar clinical (60% in both) and different quality of life scores (87.5 % in subject 2 and 68.75% in subject 3). Additional variables regarding individual traits and social-familial context should be investigated in order to explain these differences. These variables are neither predictable nor easily editable [42]. Health related quality of life describes a person’s satisfaction by integrating current life circumstances as well as the ability to cope and adjust to adversity: it is a complex construct that is strongly associated to family life, parents’ responses and well-being, the quality of the social environment and other important factors [42]. Quality of life depends on subjective appraisal rather than objective measurements [41]. It is preferable to assess overall quality of life rather than health-related quality of life and it should be defined and measured in terms of life satisfaction [41].
For both sexes it was observed that some specific items reached insufficient scores, especially sexual activity and body image for the male (31.25%). This last observation is in line with a previous study which found that boys with DSD showed impairment concerning body image: they had a more negative body image of the primary sexual characteristics compared with male controls [43]. It is important to remember regarding body image that the male subject had a reduced adult height suggesting that the possibility of growth hormone therapy should be carefully considered due to the strong effect of being short on body image perception.
Other studies investigated health-related quality of life in subjects with DSD. Kleinemeier E, Jurgensen M, Lux A, et al. observed that the psychological well-being of adolescents with DSD was not impaired, but outcomes related to adolescent developmental tasks such as sexual activity showed impaired participation and especially girls with DSD reported having fewer sexual activities than female controls [43]. For these subjects partnership and sexuality were identified as being difficult issues in life [44].
One of the females from our small cohort did not answer questions related to sexual activity and this could be due to difficulty in facing questions regarding sexual matters. Because of the elevated risk of sexuality-related problems, adequate and timely counseling regarding sexuality and relationships is of great importance: adolescents do not only need medical and sexual education, but they should also have the opportunity to discuss their concerns repeatedly with a mental health professional in private [45, 46].
There is a report in literature claiming that adolescents who needed hormonal treatment to induce puberty have impaired well being compared to those who entered puberty spontaneously [43]. It is especially important to consider this in subjects reared as male since the risk of neoplastic transformation of the gonads should be weighted taking into account the possibility of a spontaneous pubertal development in presence of functional testicles.
Although the proposed scoring system should be tested on a larger control population, the comparison of clinical outcome with gender identity and quality of life provided us with important information for using a more complete approach for treatment, including psychosocial assessment.
The results should be carefully interpreted due to the limitations of the study. The findings are not easily generalizable since it was an observational study and lacks representativeness of the affected population.
Clinical and psychosocial assessment in people with DSD is mandatory in order to better direct care processes and adequate tools are required for a detailed analysis. In this sense the Clinical scoring system, the Gender Identity Questionnaire for Children and the World Health Organization Quality of Life assessment could prove to be important tools for investigating the alignment of physical characteristics and development with gender identity and quality of life.
All authorsdeclare no conflicts of interest in this paper.
[1] | [ M. Ajelli, S. Merler, L. Fumanelli, A. Pastore, Y. Piontti, N. E. Dean, I. M. Longini Jr. , M. E. Halloran and A. Vespignani, Spatiotemporal dynamics of the Ebola epidemic in Guinea and implications for vaccination and disease elimination: A computational modeling analysis BMC Medicine 14(2016), p130. |
[2] | [ C. L. Althaus, Estimating the reproduction number of ebola virus (EBOV) during the 2014 outbreak in West Africa PLOS Currents Outbreaks (2014), Edition 1. |
[3] | [ E. J. Amundsen,H. Stigum,J. A. Rottingen,O. O. Aalen, Definition and estimation of an actual reproduction number describing past infectious disease transmission: application to HIV epidemics among homosexual men in Denmark, Norway, and Sweden, Epidemiol Infect, 132 (2004): 1139-1149. |
[4] | [ D. Bernoulli,S. Blower, An attempt at a new analysis of the mortality caused by smallpox and of the advantages of inoculation to prevent it, Reviews in Medical Virology, 14 (2004): 275-288. |
[5] | [ S. M. Blower,E. N. Bodine,K. Grovit-Ferbas, Predicting the potential public health impact of Disease-Modifying HIV Vaccines in South Africa: The problem of subtypes, Curr Drug Targets Infect Disord, 5 (2005): 179-192. |
[6] | [ S. M. Blower,H. Dowlatabadi, Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example, Int Stat Rev, 62 (1994): 229-243. |
[7] | [ C. Browne,H. Gulbudak,G. Webb, Modeling contact tracing in outbreaks with application to Ebola, J Theor Biol, 384 (2015): 33-49. |
[8] | [ S. Calvignac-Spencer, J. M. Schulze, F. Zickmann and B. Y. Renard, Clock rooting further demonstrates that Guinea 2014 EBOV is a member of the Zaïre Lineage, PLOS Currents Outbreaks (2014), Edition 1. |
[9] | [ CDC, 2014 Ebola outbreak in West Africa -Case Counts, Centers for Disease Control and Prevention (2016), http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/case-counts.html. |
[10] | [ CDC, Ebola survivors, Centers for Disease Control (2016), http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/survivors.html. |
[11] | [ CDC, Ebola virus disease -signs and symptoms, Centers for Disease Control (2015), http://www.cdc.gov/vhf/ebola/symptoms/index.html. |
[12] | [ CDC, Outbreak chronology: Ebola virus disease, Centers for Disease Control (2015), http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html. |
[13] | [ G. Chowell,N. W. Hengartner,C. Castillo-Chavez,P. W. Fenimore,J. M. Hyman, The basic reproductive number of Ebola and the effects of public health measures: The cases of Congo and Uganda, J Theor Biol, 229 (2004): 119-126. |
[14] | [ G. Chowell,M. Kiskowski, Modeling ring-vaccination strategies to control ebola virus disease epidemics, Mathematical and Statistical Modeling for Emerging and Re-emerging Infectious Diseases, null (2016): 71-87. |
[15] | [ A. Christie,G. J. Daview-Wayne,T. Cordier-Lasalle,D. J. Blackley,A. S. Laney,D. E. Williams,S. A. Shinde,M. Badio,T. Lo,S. E. Mate,J. T. Ladner,M. R. Wiley,J .R. Kugelman,G. Palacios,M. R. Holbrook,K. B. Janosko,E . de Wit,N. van Doremalen,V. J. Munster,J. Pettitt,R. J. Schoepp,L. Verhenne,I. Evlampidou,K. K. Kollie,S. B. Sieh,A. Gasasira,F. Bolay,F. N. Kateh,T. G. Nyenswah,K. M. De Cock, Possible sexual transmission of Ebola virus-Liberia, 2015, MMWR Morb Mortal Wkly Rep, 64 (2015): 479-481. |
[16] | [ CIA, The CIA World Factbook, Central Intelligence Agency, United States (2015), https://www.cia.gov/library/publications/resources/the-world-factbook/. |
[17] | [ A. Cintrón-Arias,C. Castillo-Chávez,L. M. A. Bettencourt,A. L. Lloyd,H. T. Banks, The estimation of the effective reproduction number from disease outbreak data, Math Biosci Eng, 6 (2009): 261-282. |
[18] | [ G. F. Deen,B. Knust,N. Broutet,F. R. Sesay,P. Formenty,C. Ross,A. E. Thorson,T. A. Massaquoi,J. E. Marrinan,E. Ervin,A. Jambai,S. L. R. McDonald,K. Bernstein,A. H. Wurie,M. S. Dumbuya,N. Abad,B. Idriss,T. Wi,S. D. Bennett,T. Davies,F. K. Ebrahim,E. Meites,D. Naidoo,S. Smith,A. Banerjee,B. R. Erickson,A. Brault,K. N. Durski,J. Winter,T. Sealy,S. T. Nichol,M. Lamunu,U. Ströher,O. Morgan,F. Sahr, Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors --Preliminary Report, N Engl J Med, null (2015). |
[19] | [ E. de Wit, H. Feldmann and V. J. Munsters, Tackling Ebola: New insights into prophylactic and therapeutic intervention strategies, Genome Med 3(2011). |
[20] | [ M. G. Dixon,I. J. Schafer, Ebola Viral disease outbreak --West Africa, 2014, MMRW Morb Mortal Wkly Rep, 63 (2014): 548-551. |
[21] | [ T. S. Do,Y. S. Lee, Modeling the spread of Ebola, Osong Public Health and Research Perspectives, 7 (2016): 43-48. |
[22] | [ S. F. Dowell,R. Mukunu,T. G. Ksiazek,A. S. Khan,P. E. Rollin,C. J. Peters, Transmission of Ebola hemorrhagic fever: A study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995, J Infect Dis, 179 (1999): S87-S91. |
[23] | [ P. van den Driessche,J. Watmough, Reproduction number and sub-threshold endemic equilibria for compartmental models of disease transmission, Math Biosci, 180 (2002): 29-48. |
[24] | [ M. Eichner,K. Dietz, Transmission potential of smallpox: Estimates based on detailed data from an outbreak, Amer Journal of Epidem, 158 (2003): 110-117. |
[25] | [ M. Eichner,S. F. Dowell,N. Firese, Incubation period of ebola hemorrhagic virus subtype zaire, Osong Public Heath Res Perspect, 2 (2011): 3-7. |
[26] | [ D. Fisman, E. Khoo and A. Tuite, Early epidemic dynamics of the West African 2014 Ebola outbreak: Estimates derived with a simple two-parameter model PLOS Currents Outbreaks (2014), Edition 1. |
[27] | [ T. C. Germann, K. Kadau, I. M. Longini Jr. and C. A. Macken, Mitigation strategies for pandemic influenza in the United States PNAS (2006). |
[28] | [ R. F. Grais,M. J. Ferrari,C. Dubray,O. N. Bjornstad,G. T. Grenfell,A. Djibo,F. Fermon,P. J. Guerin, Estimating transmission intensity for a measles epidemic in Niamey, Niger: Lessons for intervention, Transactions of the Royal Society of Tropical Medicine and Hygiene, 100 (2006): 867-873. |
[29] | [ J. M. Heffernan,R. J. Smith,L. M. Wahl, Perspectives on the basic reproductive ratio, J Roy Soc Interface, 2 (2005): 281-293. |
[30] | [ J. M. Heffernan,M. J. Keeling, Implications of vaccination and waning immunity, Proc R Soc B, 276 (2009): 2071-2080. |
[31] | [ A. M. Henao-Restrepo,A. Camacho,I. M. Longini,C. H. Watson,W. J. Edmunds,M. Egger,M. W. Carroll,N. E. Dean,I. Diatta,M. Doumbia,B. Draguez,S. Duraffour,G. Enwere,R. Grais,S. Gunther,P.-S. Gsell,S. Hossmann,S. V. Watle,M. K. Kondé,S. Kéïta,S. Kone,E. Kuisma,M. M. Levine,S. Mandal,T. Mauget,G. Norheim,X. Riveros,A. Soumah,S. Trelle,A. S. Vicari,J.-A. Rottingen,M.-P. Kieny, Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!), The Lancet, 389 (2017): 505-518. |
[32] | [ A. M. Henao-Restrepo,I. M. Longini,M. Egger,N. E. Dean,W. J. Edmunds,A. Camacho,M. W. Carroll,M. Doumbia,B. Draguez,S. Duraffour,G. Enwere,R. Grais,S. Gunther,S. Hossmann,M. K. Kondé,S. Kone,E. Kuisma,M. M. Levine,S. Mandal,G. Norheim,X. Riveros,A. Soumah,S. Trelle,A. S. Vicari,C. H. Watson,S. Kéïta,M. P. Kieny,J.-A. Rottingen, Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial, The Lancet, 386 (2015): 857-866. |
[33] | [ B. S. Hewlett,R. P. Amola, Cultural contexts of Ebola in Northern Uganda, Emerg Infect Dis, 9 (2003): 1242-1248. |
[34] | [ M. Ibrahim,L. Alexander,C. Shy,S. Farr, UNC Department of Epidemiology: Incidence vs. Prevalence, Epidemiologic Research & Information Center Notebook, null (1999): 1-5. |
[35] | [ A. Kahn, M. Naveed, M. Dur-e-Ahmad and M. Imran, Estimating the basic reproductive ratio for the Ebola outbreak in Liberia and Sierra Leone Infect Dis Poverty 4(2015), p13. |
[36] | [ M. J. Keeling and P. Rohani, Modeling Infectious Diseases in Humans and Animals Princeton University Press, 2008. |
[37] | [ M. J. Keeling,M. E. J. Woolhouse,R. M. May,G. Davies,B. T. Grenfell, Modelling vaccination strategies against foot-and-mouth disease, Nature, 421 (2003): 136-142. |
[38] | [ Y. Kinfu,M. R. Dal Poz,H. Mercer,D. B. Evans, The health worker shortage in Africa: Are enough physicians and nurses being trained?, Bull World Health Organ, 87 (2009): 225-230. |
[39] | [ N. M. Kudoyarova-Zubavichene,N. N. Sergeyev,A. A. Chepurnov,S. V. Netesov, Preparation and Use of Hyperimmune Serum for Prophylaxis and Therapy of Ebola Virus Infections, J Infect Dis, 179 (1999): 218-223. |
[40] | [ J. Legrand,R. F. Brais,P. Y. Boelle,A. J. Valleron,A. Flahault, Understanding the dynamics of Ebola epidemics, Epidemiol Infect, 135 (2007): 610-621. |
[41] | [ E. M. Leroy,P. Rouquet,P. Formenty,S. Souquiere,A. Kilbourne,J.-M. Froment,M. Bermejo,S. Smit,W. Karesh,R. Swanepoel,S. R. Zaki,P. E. Rollin, Multiple Ebola virus transmission events and rapid decline of Central African wildlife, Science, 303 (2004): 387-390. |
[42] | [ Y. Liu,J. Wang,S. Liu,J. Du,L. Wang,W. Gu,Y. Xu,S. Zuo,E. Xu,Z. An, Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014, Vaccine, 35 (2017): 1281-1286. |
[43] | [ S. Marino,I. B. Hogue,C. J. Ray,D. E. Kirschner, A methodology for performing global uncertainty and sensitivity analysis in systems biology, J Theor Biol, 254 (2008): 178-196. |
[44] | [ M. D. McKay,R. J. Beckman,W. J. Conover, A comparison of three methods for selecting values of input variables in the analysis of output from a computer code, Technometrics, 21 (1979): 239-245. |
[45] | [ M. I. Meltzer,C. Y. Atkins,S. Santibanez,B. Knust,B. W. Petersen,E. D. Ervin,S. T. Nichol,I. K. Damon,M. L. Washington, Estimating the future number of cases in the Ebola Epidemic --Liberia and Sierra Leone, 2014-2015, MMWR Morb Mortal Wkly Rep, null (2014). |
[46] | [ S. Merler, M. Ajelli, L. Fumanelli, S. Parlamento, A. Pastore y Piontti, N. E. Dean, G. Putoto, D. Carraro, I. M. Longini Jr. , M. E. Halloran and A. Vespignani, Containing Ebola at the source with ring vaccination PLOS Neglected Tropical Diseases 10(2016), e0005093. |
[47] | [ J. Müller,B. Schönfisch,M. Kirkilionis, Ring vaccination, Journal of Mathematical Biology, 41 (2000): 143-171. |
[48] | [ Medicins Sans Frontieres/Doctors Without Borders, Ebola (2015), http://www.doctorswithoutborders.org/our-work/medical-issues/ebola. |
[49] | [ H. Nishiura, Correcting the actual reproduction number: A simple method to estimate from early epidemic growth data, Int J Environ Res Public Health, 7 (2010): 291-302. |
[50] | [ A. Pandey,K. E. Atkins,J. Medlock,N. Wenzel,J. P. Townsend,J. E. Childs,T. G. Nyenswah,M. L. Ndeffo-Mbah,A. P. Galvani, Strategies for containing Ebola in West Africa, Science, 346 (2014): 991-995. |
[51] | [ J. Prescott,T. Bushmaker,R. Fischer,K. Miazgowicz,S. Judson,V. J. Munster, Postmortem stability of Ebola virus, Emerg Infect Dis, 21 (2015): 856-859. |
[52] | [ C. M. Rivers, E. T. Lofgren, M. Marathe, S. Eubank and B. L. Lewis, Modeling the impact of interventions on an epidemic of Ebola in sierra leone and liberia PLOS Currents Outbreaks (2014), Edition 2. |
[53] | [ D. Salem,R. Smith?, A mathematical model of ebola virus disease: Using sensitivity analysis to determine effective intervention targets, Proceedings of SummerSim-SCSC, null (2016): 16-23. |
[54] | [ E. E. Salpeter,S. R. Salpeter, Mathematical mode for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function, Am J Epidemiol, 142 (1998): 398-406. |
[55] | [ R. Smith?, Modelling Disease Ecology with Mathematics American Institute of Mathematical Sciences, 2008. |
[56] | [ L. R. Stanberry, Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines, Herpes, null (2004): 161A-169A. |
[57] | [ United Nations, Making A Difference the Global Ebola Response: Outlook 2015 United Nations, (2015), http://ebolaresponse.un.org/outlook-2015. |
[58] | [ United Nations Global Ebola Response, UN Mission for Ebola Emergency Response (UNMEER) United Nations, (2015), http://ebolaresponse.un.org/un-mission-ebola-emergency-response-unmeer. |
[59] | [ G. Webb, C. Browne, X. Huo, O. Seydi, M. Seydi and P. Magal, A model of the 2014 Ebola epidemic in West Africa with contact tracing PLoS Currents Outbreaks (2015), Edition 1. |
[60] | [ G. Webb,C. Browne, A model of the Ebola epidemics in West Africa incorporating age of infection, J Biol Dyn, 10 (2016): 18-30. |
[61] | [ WHO, WHO coordinating vaccination of contacts to contain Ebola flare-up in Guinea, World Health Organization, (2016), http://www.who.int/features/2016/ebola-contacts-vaccination/en/. |
[62] | [ WHO, One year into the Ebola epidemic: A deadly tenacious and unforgiving virus, World Health Organization, (2015), http://www.who.int/csr/disease/ebola/one-year-report/introduction/en/. |
[63] | [ WHO, Ebola outbreak 2014 -present: How the outbreak and WHO's response unfolded, World Health Organization, (2016), http://who.int/csr/disease/ebola/response/phases/en/. |
[64] | [ WHO, Ebola virus disease, World Health Organization, (2015), http://www.who.int/mediacentre/factsheets/fs103/en/. |
[65] | [ WHO, WHO: Ebola Response Roadmap World Health Organization, (2014), http://www.who.int/csr/resources/publications/ebola/response-roadmap/en/. |
[66] | [ WHO, Ebola Virus Disease Outbreak Response Plan in West Africa World Health Organization, (2014), http://www.who.int/mediacentre/factsheets/fs103/en/. |
[67] | [ WHO Ebola Response Team, Ebola Virus Disease in West Africa -The First 9 Months of the Epidemic and Forward Projections, N Engl J Med, 371 (2014): 1481-1495. |
1. | Mohammad Reza Abbaszadeh, Mehdi Jabbari Nooghabi, Mohammad Mahdi Rounaghi, Using Lyapunov’s method for analysing of chaotic behaviour on financial time series data: a case study on Tehran stock exchange, 2020, 2, 2689-3010, 297, 10.3934/NAR.2020017 | |
2. | Siming Liu, Honglei Gao, Peng Hou, Yong Tan, Risk spillover effects of international crude oil market on China’s major markets, 2019, 7, 2333-8334, 819, 10.3934/energy.2019.6.819 | |
3. | João Teodósio, 2021, chapter 8, 9781799875963, 147, 10.4018/978-1-7998-7596-3.ch008 | |
4. | Luis Otero González, Raquel Esther Querentes Hermida, Pablo Durán Santomil, Celia López Penabad, Evaluation of the performance of Spanish family businesses portfolios, 2024, 2043-6238, 10.1108/JFBM-02-2024-0036 |
Subject | Clinical presentation/Sex of rearing | Reconstructive surgery (age: years, months) | Gonadal features | Gonadal surgery (age: years, months) | Karyotype | Genitourinary imaging | Hormone levels (10th‒30th day of life) | Comorbidities |
1 | EMS 4.5/12 Female | Clitoroplasty (1, 0/12) Vaginoplasty (1, 0/12) | Right gonad: streak, intra-abdominal Left gonad: dysgenetic, inguinal | Bilateral gonadectomy (0, 3/12) | 45,X/46,XY prenatal (amniocentesis) | Uterus: present, hypoplastic Fallopian tubes: absent Urogenital sinus | FSH 3.6 mU/mL LH 2.4 mU/mL Testosterone 0.56 ng/mL | Horizontal nystagmus |
2 | EMS 0.5/12 Female | Vaginoplasty (0, 6/12) Clitoroplasty (0, 6/12–25, 0/12) Corrective surgery in vaginal introitus stenosis (25, 0/12) | Right gonad: streak, intra-abdominal Left gonad: dysgenetic, inguinal | Bilateral gonadectomy (0, 4/12) | 45,X/46,XY postnatal | Uterus: present, regular structure Fallopian tubes: absent Urogenital sinus | FSH 3.5 mU/mL LH 2.1 mU/mL Testosterone 0.42 ng/mL | None |
3 | EMS 9.5/12 Female | Vaginoplasty (1, 0/12) Clitoroplasty (1, 0/12) | Right gonad: streak, inguinal Left gonad: dysgenetic, intrascrotal | Bilateral gonadectomy (1, 0/12) | 45,X/46,XY prenatal (amniocentesis) | Uterus: present, regular structure Fallopian tubes: present on right side Female urethra: slightly longer, it flows in a small vestibule with a vagina of regular morphology | FSH 3.1 mU/mL LH 2.5 mU/mL Testosterone 0.3 ng/mL | None |
4 | EMS 4.5/12 Female | Vaginoplasty (0, 3/12) Clitoroplasty (0, 3/12) | Right gonad: dysgenetic, inguinal Left gonad: streak, intra-abdominal | Bilateral gonadectomy (0, 3/12) | 45,X/46,XY prenatal (amniocentesis) | Suspected ambiguous genitalia at prenatal ultrasound Uterus: present, regular structure Fallopian tubes: absent Vagina with moderate uterine impression at cupola level Female urethra: straight, veru montanum absent, it flows in a large vestibule with a vagina of regular morphology | FSH 11.1 mU/mL LH 6.14 mU/mL Testosterone 1.12 ng/mL | None |
5 | EMS 5/12 Male | Urethroplasty (12, 0/12) Testicular prosthesis placement (18, 10/12) | Right gonad: streak, intra-abdominal Left gonad: dysgenetic, intra-abdominal | Bilateral gonadectomy (1, 6/12) | 45,X/46,XYq- postnatal | Uterus: absent Fallopian tubes: absent Male urethra: hypospadic, veru montanum present | FSH 3.5 mU/mL LH 0.7 mU/mL Testosterone 0.8 ng/mL | None |
6 | EMS 6.5/12 Male | Chordee correction (recurvatio corrective surgery) (3, 0/12) Urethroplasty (4, 5/12) | Right gonad: regularly developed, intrascrotal Left gonad: dysgenetic, inguinal | Left gonadectomy (1, 9/12) | 45,X/46,XY postnatal | Uterus: absent Fallopian tubes: absent Male urethra: hypospadic, veru montanum present | FSH 5.4 mU/mL LH 3.2 mU/mL Testosterone 1.2 ng/mL | None |
7 | EMS 8.5/12 Male | Chordee correction (recurvatio corrective surgery) (8, 0/12) Urethroplasty (8, 0/12) | Right gonad: hypoplastic, inguinal Left gonad: regularly developed, intrascrotal | Right orchidopexy (6, 0/12) | 45,X/46,XY/47,XYY postnatal | Uterus: absent Fallopian tubes: absent Male urethra: hypospadic | FSH 4.5 mU/mL LH 2.3 mU/mL Testosterone 0.9 ng/mL | None |
8 | EMS 7.5/12 Male | Chordee correction (recurvatio corrective surgery) (1, 6/12) Urethroplasty (in two times) (2, 0/12–3, 6/12) | Right gonad: fusiform, inguinal Left gonad:dysgenetic, intra-abdominal | Right orchidopexy (0, 3/12) Left gonadectomy (0, 3/12) | 45,X/46,X, i(Y)(p11) postnatal | Uterus: absent Fallopian tubes: absent Male urethra: hypospadic, veru montanum present | FSH 11.2mU/mL LH 5.1mU/mL Testosterone 1.5ng/mL | Common Atrioventri-cular Chamber |
9 | EMS 7.5/12 Male | Hysterectomy (1, 0/12) Vaginectomy (1, 0/12) Urethroplasty (in two times) (2, 4/12–3, 0/12) | Right gonad: regularly developed, inguinal Left gonad: streak, intra-abdominal | Right orchidopexy (0, 4/12) Left gonadectomy (0, 4/12) | 45,X/46,XY postnatal | Suspected ambiguous genitalia at prenatal ultrasound Uterus: present, regular morphology Fallopian tubes: present on left side, hypoplastic Urogenital sinus in which a straight urethra flows, veru montanum absent | FSH 1.2 mU/mL LH 0.8 mU/mL Testosterone 0.3 ng/mL | None |
10 | EMS 12/12 Male | None | Right gonad: regularly developed, intrascrotal Left gonad: regularly developed, intrascrotal | None | 45,X/46,XY prenatal (amniocentesis) | Uterus: absent Fallopian tubes: absent Male urethra | FSH 4.5 mU/mL LH 1.4 mU/mL Testosterone 1.3 ng/mL | None |
Feature | Score for Yes/No or condition |
EMS | |
Scrotal fusion | 3/0 |
Micropenis | 0/3 |
Urethral meatus | |
- Normal | 3 |
- Glandular | 2 |
- Penile | 1 |
- Perineal | 0 |
Right and left gonad (score for each) | |
- Scrotal | 1.5 |
- Inguinal | 1 |
- Abdominal | 0.5 |
- Absent | 0 |
Feature | Score |
Height | |
< 3rd percentile 3rd‒10th percentile 10th‒25th percentile 25th‒50th percentile > 50th percentile | 1 2 3 4 5 |
Male genitals | |
hypospadias and recurvatio hypospadias and surgically corrected recurvatio surgically corrected hypospadias and recurvatio surgically corrected hypospadias and no recurvatio male normally shaped genitalia | 1 2 3 4 5 |
Female genitals | |
clitoral hypertrophy and urogenital sinus partial reduction of clitoral hypertrophy and urogenital sinus clitoroplasty and vaginoplasty with narrow orifice clitoroplasty and vaginoplasty female normally shaped genitalia | 1 2 3 4 5 |
Gonads | |
bilateral gonadectomy unilateral gonadectomy of a streak gonad and contralateral dysgenetic gonad bilateral dysgenetic gonads unilateral gonadectomy of a streak gonad and contralateral regularly developed gonad bilateral regularly developed gonads | 1 2 3 4 5 |
Pubertal development score: according to Tanner staging [27]. |
Subject | Age (years, month) | Height (clinical score) | Genitalia (clinical score) | Gonads (clinical score) | Pubertal development (clinical score) | Total Clinical Score | Gicq score | Whoqol-100 score | Comorbidities | |
TOTAL SCORE | 4 FACETS SCORE | |||||||||
1 | 33, 0/12 | 144.1 cm << 3rd percentile (1) | Clitoroplasty and vaginoplasty results (4) | Bilateral gonadectomy results (1) | Adult (BV, PHV) with regular menses (5) | 11/20 = 55% | - | - | - | Recurrent urinary tract infections; neurological disease (tremors, motor incoordination, nystagmus, cognitive impairment); erythematous desquamative chronic dermatitis |
2 | 31, 0/12 | 153.5 cm 3rd-10th percentile (2) | Clitoroplasty, vaginoplasty and corrective surgery in vaginal introitus stenosis results (4) | Bilateral gonadectomy results (1) | Adult (BV, PHV) with regular menses (5) | 12/20 = 60% | - | 87.5% | Self-esteem: 87.5% Body image: 93.75% Interpersonal relationships: 93.75% Sexual activity: 93.75% Average: 92.2% | None |
3 | 18, 0/12 | 158.5 cm 25th percentile (3) | Clitoroplasty results, presence of vaginal introitus stenosis (3) | Bilateral gonadectomy results (1) | Adult (BV, PHV) with regular menses (5) | 12/20 = 60% | - | 68.75% | Self-esteem: 62.5% Body image: 56.25% Interpersonal relationships: 68.75% Sexual activity: 0% Average: / | Overweight (BMI: 30 kg/mq), autoimmune thyroiditis |
4 | 1, 0/12 | 72 cm > 50th percentile (5) | Clitoroplasty and vaginoplasty results (4) | Bilateral gonadectomy results (1) | Prepubertal (-) | 10/15 = 66.7% | - | - | - | None |
5 | 26, 11/12 | 166.2 cm > 10th percentile (3) | Urethroplasty results; intrascrotal testicular prosthesis (4) | Bilateral gonadectomy results (1) | Adult (PHV, GV) (5) | 13/20 = 65% | - | - | - | Slight overweight (BMI: 26 kg/mq) |
6 | 19, 0/12 | 152.8 cm << 3rd percentile (1) | Chordee correction and urethroplasty results (3) | Rright gonad: intrascrotal, 25 mL (periodic monitoring with scrotal ultrasound and markers assessment: βhCG and αFP); Left gonad: gonadectomy results (4) | Adult (PHV, GV) (5) | 13/20 = 65% | - | 43.75% | Self-esteem: 81.25% Body image: 31.25% Interpersonal relationships: 75% Sexual activity: 6.25% Average: 48.3% | Slight overweight (BMI: 27.3 kg/mq) |
7 | 8, 0/12 | 125.8 cm 25th-50th percentile (4) | Chordee correction and urethroplasty results (3) | Right gonad: intrascrotal, 1 mL (periodic monitoring with scrotal ultrasound); Left gonad: intrascrotal, 2 mL (periodic monitoring with scrotal ultrasound) (5) | Prepubertal (-) | 12/15 = 80% | 4.80/5 = 96% | - | - | None |
8 | 6, 3/12 | 104.6 cm < 3rd percentile (1) | Chordee correction and urethroplasty results (3) | Right gonad: intrascrotal, fusiform, 1 mL (periodic monitoring with scrotal ultrasound); Left gonadectomy results (2) | Prepubertal (-) | 6/15 = 40% | 4.90/5 = 98% | - | - | Mitral regurgitation of moderate degree, hemodynamically stable (result of intervention to the atrioventricular common chamber) |
9 | 5, 2/12 | 95.5 cm < 3rd percentile (1) | Vaginectomy and urethroplasty results (3) | Right gonad: intrascrotal, 2 mL (periodic monitoring with scrotal ultrasound); Left gonadectomy results (4) | Prepubertal (-) | 8/15 = 53.3% | 4.80/5 = 96% | - | - | None |
10 | 4, 10/12 | 110 cm 50th-75th percentile (5) | Normal conformed, no reconstructive surgery (5) | Intrascrotal, 2 mL (periodic monitoring with scrotal ultrasound) (5) | Prepubertal (-) | 15/15 = 100% | 4.36/5 = 87.2% | - | - | None |
Subject | Clinical presentation/Sex of rearing | Reconstructive surgery (age: years, months) | Gonadal features | Gonadal surgery (age: years, months) | Karyotype | Genitourinary imaging | Hormone levels (10th‒30th day of life) | Comorbidities |
1 | EMS 4.5/12 Female | Clitoroplasty (1, 0/12) Vaginoplasty (1, 0/12) | Right gonad: streak, intra-abdominal Left gonad: dysgenetic, inguinal | Bilateral gonadectomy (0, 3/12) | 45,X/46,XY prenatal (amniocentesis) | Uterus: present, hypoplastic Fallopian tubes: absent Urogenital sinus | FSH 3.6 mU/mL LH 2.4 mU/mL Testosterone 0.56 ng/mL | Horizontal nystagmus |
2 | EMS 0.5/12 Female | Vaginoplasty (0, 6/12) Clitoroplasty (0, 6/12–25, 0/12) Corrective surgery in vaginal introitus stenosis (25, 0/12) | Right gonad: streak, intra-abdominal Left gonad: dysgenetic, inguinal | Bilateral gonadectomy (0, 4/12) | 45,X/46,XY postnatal | Uterus: present, regular structure Fallopian tubes: absent Urogenital sinus | FSH 3.5 mU/mL LH 2.1 mU/mL Testosterone 0.42 ng/mL | None |
3 | EMS 9.5/12 Female | Vaginoplasty (1, 0/12) Clitoroplasty (1, 0/12) | Right gonad: streak, inguinal Left gonad: dysgenetic, intrascrotal | Bilateral gonadectomy (1, 0/12) | 45,X/46,XY prenatal (amniocentesis) | Uterus: present, regular structure Fallopian tubes: present on right side Female urethra: slightly longer, it flows in a small vestibule with a vagina of regular morphology | FSH 3.1 mU/mL LH 2.5 mU/mL Testosterone 0.3 ng/mL | None |
4 | EMS 4.5/12 Female | Vaginoplasty (0, 3/12) Clitoroplasty (0, 3/12) | Right gonad: dysgenetic, inguinal Left gonad: streak, intra-abdominal | Bilateral gonadectomy (0, 3/12) | 45,X/46,XY prenatal (amniocentesis) | Suspected ambiguous genitalia at prenatal ultrasound Uterus: present, regular structure Fallopian tubes: absent Vagina with moderate uterine impression at cupola level Female urethra: straight, veru montanum absent, it flows in a large vestibule with a vagina of regular morphology | FSH 11.1 mU/mL LH 6.14 mU/mL Testosterone 1.12 ng/mL | None |
5 | EMS 5/12 Male | Urethroplasty (12, 0/12) Testicular prosthesis placement (18, 10/12) | Right gonad: streak, intra-abdominal Left gonad: dysgenetic, intra-abdominal | Bilateral gonadectomy (1, 6/12) | 45,X/46,XYq- postnatal | Uterus: absent Fallopian tubes: absent Male urethra: hypospadic, veru montanum present | FSH 3.5 mU/mL LH 0.7 mU/mL Testosterone 0.8 ng/mL | None |
6 | EMS 6.5/12 Male | Chordee correction (recurvatio corrective surgery) (3, 0/12) Urethroplasty (4, 5/12) | Right gonad: regularly developed, intrascrotal Left gonad: dysgenetic, inguinal | Left gonadectomy (1, 9/12) | 45,X/46,XY postnatal | Uterus: absent Fallopian tubes: absent Male urethra: hypospadic, veru montanum present | FSH 5.4 mU/mL LH 3.2 mU/mL Testosterone 1.2 ng/mL | None |
7 | EMS 8.5/12 Male | Chordee correction (recurvatio corrective surgery) (8, 0/12) Urethroplasty (8, 0/12) | Right gonad: hypoplastic, inguinal Left gonad: regularly developed, intrascrotal | Right orchidopexy (6, 0/12) | 45,X/46,XY/47,XYY postnatal | Uterus: absent Fallopian tubes: absent Male urethra: hypospadic | FSH 4.5 mU/mL LH 2.3 mU/mL Testosterone 0.9 ng/mL | None |
8 | EMS 7.5/12 Male | Chordee correction (recurvatio corrective surgery) (1, 6/12) Urethroplasty (in two times) (2, 0/12–3, 6/12) | Right gonad: fusiform, inguinal Left gonad:dysgenetic, intra-abdominal | Right orchidopexy (0, 3/12) Left gonadectomy (0, 3/12) | 45,X/46,X, i(Y)(p11) postnatal | Uterus: absent Fallopian tubes: absent Male urethra: hypospadic, veru montanum present | FSH 11.2mU/mL LH 5.1mU/mL Testosterone 1.5ng/mL | Common Atrioventri-cular Chamber |
9 | EMS 7.5/12 Male | Hysterectomy (1, 0/12) Vaginectomy (1, 0/12) Urethroplasty (in two times) (2, 4/12–3, 0/12) | Right gonad: regularly developed, inguinal Left gonad: streak, intra-abdominal | Right orchidopexy (0, 4/12) Left gonadectomy (0, 4/12) | 45,X/46,XY postnatal | Suspected ambiguous genitalia at prenatal ultrasound Uterus: present, regular morphology Fallopian tubes: present on left side, hypoplastic Urogenital sinus in which a straight urethra flows, veru montanum absent | FSH 1.2 mU/mL LH 0.8 mU/mL Testosterone 0.3 ng/mL | None |
10 | EMS 12/12 Male | None | Right gonad: regularly developed, intrascrotal Left gonad: regularly developed, intrascrotal | None | 45,X/46,XY prenatal (amniocentesis) | Uterus: absent Fallopian tubes: absent Male urethra | FSH 4.5 mU/mL LH 1.4 mU/mL Testosterone 1.3 ng/mL | None |
Feature | Score for Yes/No or condition |
EMS | |
Scrotal fusion | 3/0 |
Micropenis | 0/3 |
Urethral meatus | |
- Normal | 3 |
- Glandular | 2 |
- Penile | 1 |
- Perineal | 0 |
Right and left gonad (score for each) | |
- Scrotal | 1.5 |
- Inguinal | 1 |
- Abdominal | 0.5 |
- Absent | 0 |
Feature | Score |
Height | |
< 3rd percentile 3rd‒10th percentile 10th‒25th percentile 25th‒50th percentile > 50th percentile | 1 2 3 4 5 |
Male genitals | |
hypospadias and recurvatio hypospadias and surgically corrected recurvatio surgically corrected hypospadias and recurvatio surgically corrected hypospadias and no recurvatio male normally shaped genitalia | 1 2 3 4 5 |
Female genitals | |
clitoral hypertrophy and urogenital sinus partial reduction of clitoral hypertrophy and urogenital sinus clitoroplasty and vaginoplasty with narrow orifice clitoroplasty and vaginoplasty female normally shaped genitalia | 1 2 3 4 5 |
Gonads | |
bilateral gonadectomy unilateral gonadectomy of a streak gonad and contralateral dysgenetic gonad bilateral dysgenetic gonads unilateral gonadectomy of a streak gonad and contralateral regularly developed gonad bilateral regularly developed gonads | 1 2 3 4 5 |
Pubertal development score: according to Tanner staging [27]. |
Subject | Age (years, month) | Height (clinical score) | Genitalia (clinical score) | Gonads (clinical score) | Pubertal development (clinical score) | Total Clinical Score | Gicq score | Whoqol-100 score | Comorbidities | |
TOTAL SCORE | 4 FACETS SCORE | |||||||||
1 | 33, 0/12 | 144.1 cm << 3rd percentile (1) | Clitoroplasty and vaginoplasty results (4) | Bilateral gonadectomy results (1) | Adult (BV, PHV) with regular menses (5) | 11/20 = 55% | - | - | - | Recurrent urinary tract infections; neurological disease (tremors, motor incoordination, nystagmus, cognitive impairment); erythematous desquamative chronic dermatitis |
2 | 31, 0/12 | 153.5 cm 3rd-10th percentile (2) | Clitoroplasty, vaginoplasty and corrective surgery in vaginal introitus stenosis results (4) | Bilateral gonadectomy results (1) | Adult (BV, PHV) with regular menses (5) | 12/20 = 60% | - | 87.5% | Self-esteem: 87.5% Body image: 93.75% Interpersonal relationships: 93.75% Sexual activity: 93.75% Average: 92.2% | None |
3 | 18, 0/12 | 158.5 cm 25th percentile (3) | Clitoroplasty results, presence of vaginal introitus stenosis (3) | Bilateral gonadectomy results (1) | Adult (BV, PHV) with regular menses (5) | 12/20 = 60% | - | 68.75% | Self-esteem: 62.5% Body image: 56.25% Interpersonal relationships: 68.75% Sexual activity: 0% Average: / | Overweight (BMI: 30 kg/mq), autoimmune thyroiditis |
4 | 1, 0/12 | 72 cm > 50th percentile (5) | Clitoroplasty and vaginoplasty results (4) | Bilateral gonadectomy results (1) | Prepubertal (-) | 10/15 = 66.7% | - | - | - | None |
5 | 26, 11/12 | 166.2 cm > 10th percentile (3) | Urethroplasty results; intrascrotal testicular prosthesis (4) | Bilateral gonadectomy results (1) | Adult (PHV, GV) (5) | 13/20 = 65% | - | - | - | Slight overweight (BMI: 26 kg/mq) |
6 | 19, 0/12 | 152.8 cm << 3rd percentile (1) | Chordee correction and urethroplasty results (3) | Rright gonad: intrascrotal, 25 mL (periodic monitoring with scrotal ultrasound and markers assessment: βhCG and αFP); Left gonad: gonadectomy results (4) | Adult (PHV, GV) (5) | 13/20 = 65% | - | 43.75% | Self-esteem: 81.25% Body image: 31.25% Interpersonal relationships: 75% Sexual activity: 6.25% Average: 48.3% | Slight overweight (BMI: 27.3 kg/mq) |
7 | 8, 0/12 | 125.8 cm 25th-50th percentile (4) | Chordee correction and urethroplasty results (3) | Right gonad: intrascrotal, 1 mL (periodic monitoring with scrotal ultrasound); Left gonad: intrascrotal, 2 mL (periodic monitoring with scrotal ultrasound) (5) | Prepubertal (-) | 12/15 = 80% | 4.80/5 = 96% | - | - | None |
8 | 6, 3/12 | 104.6 cm < 3rd percentile (1) | Chordee correction and urethroplasty results (3) | Right gonad: intrascrotal, fusiform, 1 mL (periodic monitoring with scrotal ultrasound); Left gonadectomy results (2) | Prepubertal (-) | 6/15 = 40% | 4.90/5 = 98% | - | - | Mitral regurgitation of moderate degree, hemodynamically stable (result of intervention to the atrioventricular common chamber) |
9 | 5, 2/12 | 95.5 cm < 3rd percentile (1) | Vaginectomy and urethroplasty results (3) | Right gonad: intrascrotal, 2 mL (periodic monitoring with scrotal ultrasound); Left gonadectomy results (4) | Prepubertal (-) | 8/15 = 53.3% | 4.80/5 = 96% | - | - | None |
10 | 4, 10/12 | 110 cm 50th-75th percentile (5) | Normal conformed, no reconstructive surgery (5) | Intrascrotal, 2 mL (periodic monitoring with scrotal ultrasound) (5) | Prepubertal (-) | 15/15 = 100% | 4.36/5 = 87.2% | - | - | None |